BTLA antibodies
US11421030B2 · kind B2 · utility
0Cited by
12References
28Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 25, 2021 |
| Grant date | Aug 23, 2022 |
| Priority date | — |
| Expiry date | Jul 21, 2041 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates generally to antibodies or antigen binding fragments that bind to human B and T lymphocyte attenuator (BTLA) and uses thereof. More specifically, the invention relates to agonistic antibodies that bind human BTLA and modulate its activity, and their use in treating inflammatory, autoimmune and proliferative diseases and disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.